Evidence map›Paper›PMID 37783836›Full record

ArticleProstate cancer and prostatic diseases2024

Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.

Stephen J Freedland, Matthew Davis, Andrew J Epstein, Bhakti Arondekar, Jasmina I Ivanova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Assessment of the therapeutic efficacy of [European journal of nuclear medicine and molecular imaging · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Final overall survival and safety analyses of the phase III PSMAfore trial of [Annals of oncology : official journal of the European Society for Medical Oncology · 2025
    Trial
  12. Lancet (London, England) · 2024
    Trial
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Cost-Effectiveness Analysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stephen J FreedlandDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-8104-6419
Matthew DavisMedicus Economics, LLC, Milton, MA, USA.
Andrew J EpsteinMedicus Economics, LLC, Milton, MA, USA.
Bhakti ArondekarPfizer Inc., Collegeville, PA, USA.ORCID 0000-0002-4553-0094
Jasmina I IvanovaPfizer Inc., New York, NY, USA. Jasmina.Ivanova@pfizer.com.ORCID 0000-0002-4028-9676

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-world treatment patterns and survival in metastatic castration-resistant prostate cancer (mCRPC) have not been characterized for the full fee-for-service Medicare population.

methodsMen newly diagnosed with mCRPC were identified in Medicare fee-for-service claims during 1/1/2014-6/30/2019. Men had evidence of mCRPC and continuous insurance coverage ≥1 year before and ≥6 months after diagnosis unless patients died. Treatment patterns after diagnosis were described. Survival from mCRPC diagnosis and from start of first-line (1 L) therapy was modeled using Kaplan-Meier analysis.

resultsAmong 14,780 men with mCRPC, mean age was 76 and median follow-up after mCRPC was 17.0 months. 22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs. Median time from start of 1 L to next LOT or end of follow-up was 13.7 months, 10.9 months from 2 L start, and 8.9 months from 3 L start. The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%). For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy. Median survival was 25.6 months after mCRPC and 23.4 months following treatment initiation.

conclusionsMore than 1 in 5 Medicare patients with mCRPC did not receive any life-prolonging therapy, and less than half received 2 L therapy. NHTs were the most common 1 L and 2 L therapies, with patients treated with NHT as 1 L followed by a different NHT for 2 L as the most common treatment sequence. Median survival from diagnosis for all patients was 25.6 months. These data highlight the dramatic undertreatment that occurs for mCRPC patients, particularly for therapies beyond NHTs as well as the common use of sequential NHTs in real-world data.

Indexed as

MedicareProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overFollow-Up StudiesHumansMaleNeoplasm MetastasisPrognosisRetrospective StudiesSurvival RateUnited States

Identifiers

PMID37783836
PMCPMC11096091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.